Relay Therapeutics, Inc.
RLAY Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$18.18
KIRA · Stoqly’s AI analyst, in plain words
- Relay Therapeutics, Inc. had $15.4M of revenue in fiscal 2025, up 53.4% on the year before. Over five years, revenue changed −28.6% a year on average.
- Its operating margin was −1,971.6%, up 1,750.5 pts: of every 100 in sales, about −1,972 is left after running the business.
- Relay Therapeutics, Inc. lost $276M in fiscal 2025.
- Free cash flow was −$236M in fiscal 2025, −1,536.1% of revenue.
Market cap
—
P/E
—
Revenue
$15.4M
Net income
−$276M
Free cash flow
−$236M
Operating margin
−1,971.6%
Relay Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+53.4%
Yes. Sales grew 53.4% last year.
Does it make a profit?
−1,800.6%
No. It lost money last year.
Does profit turn into cash?
−1,536.1%
No. It spent more cash than it brought in.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Relay Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Relay Therapeutics, Inc.
- CIK
- 0001812364
Relay Therapeutics, Inc. · RLAY
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.0M | $1.4M | $25.5M | $10.0M | $15.4M |
| Revenue growth | −96.3% | −54.4% | 1,749.8% | −60.8% | 53.4% |
| Operating margin | −12,040.2% | −21,670.9% | −1,460.1% | −3,722.1% | −1,971.6% |
| Net income | −$364M | −$291M | −$342M | −$338M | −$276M |
| Net margin | −12,012.9% | −21,036.1% | −1,338.7% | −3,374.7% | −1,800.6% |
| Diluted EPS | −$3.82 | −$2.59 | −$2.79 | −$2.36 | −$1.61 |
| Cash | |||||
| Cash from operations | −$74.4M | −$229M | −$300M | −$249M | −$235M |
| Capital expenditure | $3.5M | $9.1M | $4.1M | $2.0M | $0.4M |
| Free cash flow | −$77.9M | −$239M | −$304M | −$251M | −$236M |
| FCF margin | −2,571.0% | −17,273.9% | −1,191.7% | −2,509.5% | −1,536.1% |
| Share count change | 123.2% | 18.0% | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $280M | $152M | $144M | $124M | $84.0M |
| Shareholders' equity | $898M | $950M | $752M | $778M | $567M |
| Current ratio | 40.1x | 16.0x | 25.4x | 16.0x | 22.6x |
| Returns and quality | |||||
| Return on equity | −43.8% | −31.4% | −40.2% | −44.2% | −41.1% |
| Return on tangible equity | −40.6% | −30.6% | −45.6% | −43.4% | −48.8% |
| Piotroski F-score | 1 | 2 | — | — | — |
| Altman Z'' | 9.8 | 7.4 | 6.0 | 5.1 | 3.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$130M
5 insiders
Of sales under plans
9%
$11.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Relay Therapeutics, Inc. · RLAY
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $18.18 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001812364). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.